KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) EBIT (2020 - 2023)

Historic EBIT for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$66.1 million.

  • AbCellera Biologics' EBIT fell 7484.51% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 20955.84%. This contributed to the annual value of -$314.8 million for FY2024, which is 3269.68% down from last year.
  • Per AbCellera Biologics' latest filing, its EBIT stood at -$66.1 million for Q4 2023, which was down 7484.51% from -$54.9 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' EBIT registered a high of $225.0 million during Q1 2022, and its lowest value of -$66.1 million during Q4 2023.
  • Over the past 4 years, AbCellera Biologics' median EBIT value was -$4.6 million (recorded in 2020), while the average stood at $21.2 million.
  • Within the past 5 years, the most significant YoY rise in AbCellera Biologics' EBIT was 754929.31% (2021), while the steepest drop was 148914.03% (2021).
  • Quarter analysis of 4 years shows AbCellera Biologics' EBIT stood at $160.8 million in 2020, then plummeted by 49.28% to $81.6 million in 2021, then crashed by 146.32% to -$37.8 million in 2022, then tumbled by 74.85% to -$66.1 million in 2023.
  • Its EBIT stands at -$66.1 million for Q4 2023, versus -$54.9 million for Q3 2023 and -$51.4 million for Q2 2023.